Weekly Sepsis Research Analysis
This week’s sepsis literature emphasizes mechanism-forward endotyping and targetable mitochondrial and immune pathways with translational potential. A Redox Biology study identifies SERPINE1 disrupting mitochondrial NAD/Sirt3 to drive epithelial ferroptosis in ARDS, offering a new druggable axis. A Clinical cohort in Critical Care defines a phosphorylated TLR4 high‑risk sepsis endotype that could enable biomarker-guided trials. Single-cell and signaling studies (e.g., IL‑6/STAT3→OXPHOS→AP‑1 in f
Summary
This week’s sepsis literature emphasizes mechanism-forward endotyping and targetable mitochondrial and immune pathways with translational potential. A Redox Biology study identifies SERPINE1 disrupting mitochondrial NAD/Sirt3 to drive epithelial ferroptosis in ARDS, offering a new druggable axis. A Clinical cohort in Critical Care defines a phosphorylated TLR4 high‑risk sepsis endotype that could enable biomarker-guided trials. Single-cell and signaling studies (e.g., IL‑6/STAT3→OXPHOS→AP‑1 in fibroblasts) further refine cellular endotypes that map to therapeutic opportunities.
Selected Articles
1. SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD
SERPINE1/PAI‑1 is upregulated in human ARDS and preclinical ARDS models and disrupts mitochondrial NAD/NADH–Sirt3 signaling to trigger epithelial ferroptosis. Genetic or pharmacologic SERPINE1 inhibition reduced lung injury and restored ferroptosis-protection pathways (SLC7A11/GPX4/FTH1) in vivo and in vitro, suggesting a metabolically driven, targetable axis for sepsis-related ARDS.
Impact: Uncovers a novel upstream regulator of ferroptosis linking inflammation to mitochondrial redox imbalance and epithelial death in ARDS, presenting a clear, druggable metabolic axis (SERPINE1–NAD/Sirt3) with supportive human and preclinical data.
Clinical Implications: Provides a mechanistic rationale to test PAI‑1/SERPINE1 inhibitors or metabolic modulators that preserve mitochondrial NAD/Sirt3 signaling in translational ARDS/sepsis studies to reduce epithelial ferroptosis and improve outcomes.
Key Findings
- SERPINE1 expression elevated in ARDS patients, ARDS mouse lungs, and LPS-treated AT2 cells; correlated with severity.
- Genetic or pharmacologic SERPINE1 inhibition reduced lung injury and ferroptosis markers and restored SLC7A11/GPX4/FTH1.
- Mechanistic link: SERPINE1 disrupts mitochondrial NAD/NADH–Sirt3 signaling to drive ferroptosis.
2. Phosphorylated toll-like receptor 4 defines a high-risk sepsis endotype.
In a prospective cohort of 100 sepsis patients, a proximity ligation assay quantified TLR4 phosphorylation in PBMCs at Day 1 and Day 4. While overall TLR4 activation was low, a subset with elevated phospho‑TLR4 had significantly higher 30‑day mortality (Day1 HR 2.03; Day4 HR 2.77), independent of SOFA, age, sex, and infection focus, supporting a biomarker‑guided enrichment strategy for TLR4‑targeted therapies.
Impact: Provides a functional receptor-activation biomarker that stratifies mortality risk and explains prior trial failures of TLR4 antagonists by revealing that only a subset exhibits in vivo receptor activation.
Clinical Implications: Supports development and clinical validation of phospho‑TLR4 assays to enrich patients for TLR4‑directed interventions and avoid exposing low‑activation patients to ineffective therapies.
Key Findings
- Phospho‑TLR4 quantified by proximity ligation assay showed low median activation but a distinct high‑activation subgroup.
- Elevated activation predicted reduced 30‑day survival at Day1 (HR 2.03) and Day4 (HR 2.77) and remained significant after multivariable adjustment.
- Suggests biomarker‑guided precision medicine approaches for TLR4 antagonists.
3. IL-6/STAT3 signaling drives mitochondrial oxidative phosphorylation dysfunction and AP-1 activation in fibroblasts during sepsis-induced lung injury.
Single-cell and functional studies show fibroblasts adopt inflammatory/profibrotic states in sepsis with IL‑6/STAT3 activation linked to impaired mitochondrial OXPHOS, increased mitochondrial ROS, and AP‑1 activation driving profibrotic programs. Clinically used glucocorticoids attenuated the IL‑6/STAT3–OXPHOS–AP‑1 axis and reduced lung injury and fibrosis in experimental models, connecting endotyping to an actionable intervention.
Impact: Bridges single‑cell endotyping to a modifiable pathway with existing drugs (glucocorticoids), offering a plausible mechanism for timing/selection of anti‑inflammatory therapy in sepsis‑associated lung injury.
Clinical Implications: Supports further evaluation of IL‑6/STAT3 and mitochondrial OXPHOS signatures as biomarkers to guide steroid or metabolic therapy in sepsis‑associated ALI/fibrosis and to design precision trials testing such modulation.
Key Findings
- Fibroblasts shift to proinflammatory/profibrotic states during sepsis with increased IL‑6/STAT3 activity.
- IL‑6/STAT3 associates with impaired OXPHOS, higher mitochondrial ROS, and AP‑1 activation driving profibrotic protein expression.
- Dexamethasone and methylprednisolone attenuated lung injury and fibrosis by suppressing this axis in experimental models.